Yuyu Pharma 000220.KS · KRW

Its shares trade on KRX under the ticker 000220.KS. It has been listed since 18 November 1975. In the fiscal year to 31 December 2025, it reported revenue of ₩140.88bn and net income of ₩8.15bn. At that date it held total assets of ₩207.22bn and shareholders' equity of ₩129.63bn.

Yuyu Pharma, Inc. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Jecheon, Chungcheongbuk-Do. The firm produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. The company also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Won Sang YooPresident, Co-Chief Executive Officer, Director₩625.0m
• Mr. No Yong ParkCo-Chief Executive Officer, Director, since 2021
• Mr. Jun Hui CheonAssistant Managing Director
• Mr. Laxmikant GharatAssistant Managing Director
• Mr. Jae Won JangAssistant Managing Director
• Mr. Gyeong Won KimAssistant Managing Director
• Mr. Chang Yun LeeAssistant Managing Director
• Mr. Seung Pyo WooAssistant Managing Director
• Mr. Sang Eon JooNon-Executive Independent Director
• Mr. Seung Wu LeeNon-Executive Independent Director
• Mr. Yin Ho ParkNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.